Macrogenics (MGNX) Reports Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
Tweet Send to a Friend
MacroGenics, Inc. (NASDAQ: MGNX) today announced positive results from SOPHIA, the Company’s Phase 3 clinical study of margetuximab in HER2-positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
